SciBase Passes 400,000 Nevisense Tests, Eyes Expansion Beyond Melanoma
Event summary
- SciBase has sold over 400,000 Nevisense tests globally.
- Nevisense is the only FDA-approved and CE-marked non-invasive diagnostic for melanoma risk assessment.
- A late-2025 clinical study demonstrated Nevisense's ability to predict atopic dermatitis in newborns.
- SciBase entered a collaboration with Castle Biosciences in 2025 to explore new diagnostic applications.
The big picture
SciBase's milestone underscores the growing demand for AI-powered, non-invasive diagnostic tools in dermatology. The company's strategic pivot beyond melanoma detection, particularly into preventative care for conditions like atopic dermatitis, represents a significant expansion of its addressable market. The partnership with Castle Biosciences suggests a broader strategy of leveraging Nevisense's platform for a wider range of dermatological applications, but also introduces integration and execution risks.
What we're watching
- Clinical Validation
- The success of Nevisense's expansion into atopic dermatitis diagnosis hinges on the results of the larger clinical studies currently underway, which will determine its utility and potential reimbursement pathways.
- Partnership Impact
- The collaboration with Castle Biosciences will likely shape SciBase's future product pipeline and market reach, and its effectiveness will depend on the integration of their respective technologies and commercial capabilities.
- Market Adoption
- Continued growth in Nevisense sales will require sustained adoption by dermatologists, which is contingent on demonstrating clear clinical and economic benefits compared to existing diagnostic methods.
Related topics